logo
The unbearable obviousness of AI fitness summaries

The unbearable obviousness of AI fitness summaries

The Verge3 days ago
After nearly a decade of wearables testing, I've amassed a truly terrifying amount of health and fitness data. And while I enjoy poring over my daily data, there's one part I've come to loathe: AI summaries.
Over the last two years, a deluge of AI-generated summaries has been sprinkled into every fitness, wellness, and wearable app. Strava introduced a feature called Athlete Intelligence, pitched as AI taking your raw workout data and relaying it to you in 'plain English.' Whoop has Whoop Coach, an AI chatbot that gives you a 'Daily Outlook' report summarizing the weather, your recent activity and recovery metrics, and workout suggestions. Oura added Oura Advisor, another chatbot that summarizes data and pulls out long-term trends. Even my bed greets me with summaries every morning of how its AI helped keep me asleep every night.
Each platform's AI has its nuances, but the typical morning summary goes a bit like this:
Good morning! You slept 7 hours last night with a resting heart rate of 60 bpm. That's in line with your weekly average, but your slightly elevated heart rate suggests you may not be fully recovered. If you feel tired, try going to bed earlier tonight. Health is all about balance!
That might seem helpful, but those summaries are usually placed next to a chart with the same data. It's worse for workouts. Here's one that Strava's Athlete Intelligence generated for a recent run:
Intense run with high heart rate zones, pushing into anaerobic territory and logging a relative effort well above your typical range.
Thanks? I can ask Athlete Intelligence to 'say more,' but it regurgitates my effort, heart rate zone, and pace metrics I can see in graphs in the workout summary. If you didn't know anything about my athletic history or the circumstances surrounding this run, this summary might read as insightful. Here's what the summary left out:
A more helpful insight might've been: 'You ran during record-breaking heat for your region. While you maintained a consistent and steady pace, you have a bad habit of ramping up mileage too quickly after prolonged breaks, leading to several self-reported injuries in the past five years. A safer alternative would be lower mileage runs over two weeks to acclimate to rising temperatures. Since you're injured, stick to low-intensity walks until your wounds have healed.'
Runna, a popular running app that also features AI insights, generated a slightly more useful summary. It said my next run should be 'easy,' one that's perfectly timed for me to recharge. I'm sorry, but 48 hours isn't enough time for my knees to safely heal without risk of re-opening my wounds.
The in-app chatbots aren't much better. Yesterday morning, I asked Whoop Coach if I should run today because I injured myself on my last run. It told me: 'Whoop is unable to reply to the message you sent. Please try sending a different message.' I tried reframing my prompt, saying, 'I'm injured and have a limp. Generate a low-intensity workout alternative while I recover.' I was prompted to contact Whoop Membership Services to continue the conversation.
Oura Advisor was more helpful, noting in my daily summary: 'With your Readiness dipping and recent stressors like heat, an injury, and higher glucose, your body may feel more fatigued than usual today.' It suggested I prioritize rest. When asked, 'What types of movement are okay when you have an injured knee and a slight limp?' it responded with common-sense answers like a short and easy walk if there's no pain, light stretching, and a reminder to completely rest if I feel any sharp discomfort. This is closer to an ideal response, but I had to guide it to the type of answer I wanted. The insights are so general-purpose that they benefit self-quantification newbies — and even then, only if they're allergic to googling.
My botched run is exactly the type of scenario where tech CEOs say AI insights could be most useful. In theory, I agree! It would be nice to have a competent, built-in chatbot that I could ask more nuanced questions.
For example, I've had an irregular sleep schedule this month. I asked Oura Advisor if my sleep and readiness trends showed signs of an elevated risk of injury. I also asked if I had abnormally high levels of sleep debt this month. In both cases, it said no — it said I was improving.
What resulted was an hour-long debate with a chatbot that left me questioning my own lived experience. When I tried asking it to delve into a particularly stressful week earlier this month, it told me its insights were 'limited to [my] most recent week and current trends.' That sort of defeats the point of having six years' worth of Oura data.
After months of perusing Reddit and other community forums, I know I'm not the only person who finds these AI features to be laughable. And yet, Holly Shelton, Oura's chief product officer, tells me that the response to Oura Advisor has been 'overwhelmingly positive,' with 60 percent of users using it multiple times a week and 20 percent using it daily. 'Beyond frequency,' Shelton says, 'It's delivering real impact: 60 percent say Advisor has helped them better understand metrics or health concepts they previously found confusing.'
Meanwhile, Strava spokesperson Brian Bell tells me Athlete Intelligence was intended to help beginner athletes and that 'the response to the feature remains strong' with about '80 percent of those opting in to give feedback finding the feature 'very helpful' to 'helpful.''
A Whoop spokesperson wasn't able to respond by publication.
These milquetoast summaries? They're probably the best compromise between speed, cost, usefulness, data privacy, and legal liability
I understand my frustrations stem from the inherent limitations of LLMs and the messiness of private health data. Strava might be a de facto fitness data hub, but it lacks all the health data points necessary to create holistic, useful, and personalized insights. It'd take Oura Advisor a long time to crunch a year's worth of sleep data for trends. That latency is guaranteed to offer a bad user experience. Not to mention, they'd likely have to up their subscription from $5.99 a month to add that type of computing power. I'm not sure, but Whoop Coach may have declined my injury-related queries to protect itself from liability if something bad happened to me from following its suggestions. These milquetoast summaries are probably the best compromise between speed, cost, usefulness, data privacy, and legal liability. But if that's the case, then let's be honest. Current AI features are repackaged data, much like book reports written by a fourth-grader relying on a Wikipedia summary instead of reading the book. It's a feature tacked on with duct tape and a dream because AI is the zeitgeist. Perhaps one day, these AI insights will create a useful and personalized experience with actionable insights. That day is not today, and it's not worth paying extra for.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

OpenAI employees share their 3 favorite tips for using ChatGPT
OpenAI employees share their 3 favorite tips for using ChatGPT

Business Insider

time28 minutes ago

  • Business Insider

OpenAI employees share their 3 favorite tips for using ChatGPT

If you ever happen to see Nick Turley, the head of ChatGPT at OpenAI, muttering to himself on a weekday morning, it might be because he's talking to a chatbot. Turley said that ChatGPT's voice feature is his favorite tip for using the technology on a recent episode of the OpenAI podcast. "On my way to work, I'll use it to process my own thoughts. With some luck, and I think this works most days, I'll have the restructured list of to-dos by the time I actually get there," he said, adding that the voice feature isn't yet mainstream because there are a bunch of small "kinks" still. He said he finds it valuable to force himself to articulate his thoughts aloud, and wants to see the feature improve next year. Mark Chen, OpenAI's chief research officer, said on the podcast that he's a fan of the deep research feature, especially before an introduction. "When I go meet someone new, when I'm going to talk to someone about AI, I just preflight topics," Chen said. "I think the model can do a really good job of contextualizing who I am, who I'm about to meet, and what things we might find interesting." And podcast host Andrew Mayne, who was formerly OpenAI's science communicator and worked on ChatGPT, said he uses the technology when he's out at a restaurant. "I take a photograph of a menu and I'm like, 'Help me plan a meal or whatever, I'm trying to stick to a diet," Mayne said. Turley, however, cautioned against using the same trick for the wine list. "It keeps embarrassing me with hallucinated wine recommendations, and I go order it and they're like, 'Never heard of this one,'" he said. Corporate executives across companies are using AI in their daily lives, and OpenAI CEO Sam Altman is no different. Altman said on the "ReThinking" podcast in January that he uses it in "the boring ways," for things like processing emails and summarizing documents. When Altman spoke on the OpenAI podcast in June, he said that he uses ChatGPT "constantly" as a father. At the time, he said he was mainly using it to research developmental stages. "Clearly, people have been able to take care of babies without ChatGPT for a long time," Altman said. "I don't know how I would have done that."

HRT ‘can raise breast cancer risk' in younger women
HRT ‘can raise breast cancer risk' in younger women

Yahoo

time28 minutes ago

  • Yahoo

HRT ‘can raise breast cancer risk' in younger women

Hormone replacement therapy can raise the risk of breast cancer in some younger women, a Lancet study suggests. An international team of researchers found the treatment was not linked to young onset breast cancer overall. But oestrogen plus progestin therapy appears to increase breast cancer risk by 10 per cent. Meanwhile, oestrogen hormone therapy use appeared to decrease breast cancer risk by 14 per cent. Hormone replacement therapy is a treatment used to help menopause symptoms. There are different types of HRT, which is used to treat menopause symptoms, available. They contain different hormones: some are oestrogen products; others contain progestogen and other types have both. These medicines can be taken or used in different ways and work by replacing the hormones oestrogen and progesterone, which can fall to lower levels as women approach the menopause. Most studies examining links between hormone therapy and breast cancer risk have been explored in older women. Previous work, which has focused on women who have already been through the menopause, suggest that oestrogen plus progestin hormone therapy is a risk factor for breast cancer. The researchers, led by academics from the National Institute of Environmental Health Sciences in the US, wanted to explore the risks among younger women on hormone therapy – who may take these drugs after gynaecological surgery or during perimenopause. The new meta-analysis published in the journal, Lancet Oncology, examined data drawn from previous studies of 459,476 women aged 16 to 54 years old. Some two per cent of this group (8,455) developed young-onset breast cancer, which means the disease was diagnosed before they were 55 years old. And 15 per cent of women involved in the study reported using hormone therapy, with oestrogen plus progestin hormone therapy and oestrogen being the most common types. 'Although the strength of these associations might vary by age at first use, duration of use, gynaecological surgery status, and other factors, unopposed oestrogen hormone therapy use appears to decrease breast cancer risk and oestrogen plus progestin therapy appears to increase breast cancer risk,' the authors wrote. 'The findings can be used to augment clinical recommendations for hormone therapy use in young women, for whom guidance was previously scarce.' Dr Kotryna Temcinaite, the head of research communications at Breast Cancer Now, said: 'These results are largely in line with what we already know about taking HRT for menopausal symptoms and its effects on breast cancer risk – for most people, the risk of developing breast cancer because of taking HRT is small and is outweighed by the benefits. 'Taking HRT is a very personal decision and, as such, it's vital that everyone has the information they need on the benefits and risks, discusses them with their GP or specialist team and is supported to make the choice that's right for them.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Elevance Health Insiders Sold US$6.9m Of Shares Suggesting Hesitancy
Elevance Health Insiders Sold US$6.9m Of Shares Suggesting Hesitancy

Yahoo

time29 minutes ago

  • Yahoo

Elevance Health Insiders Sold US$6.9m Of Shares Suggesting Hesitancy

Over the past year, many Elevance Health, Inc. (NYSE:ELV) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider transactions, knowing whether insiders are buying is usually more beneficial than knowing whether they are selling, as the latter can be open to many interpretations. However, if numerous insiders are selling, shareholders should investigate more. While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. In the last twelve months, the biggest single sale by an insider was when the Executive VP & President of Commercial Health Benefits, Charles Kendrick, sold US$3.2m worth of shares at a price of US$432 per share. That means that an insider was selling shares at around the current price of US$396. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern. Elevance Health insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below! View our latest analysis for Elevance Health If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar). Over the last three months, we've seen significant insider selling at Elevance Health. Specifically, Executive VP & CFO Mark Kaye ditched US$1.9m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain. For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Elevance Health insiders own 0.1% of the company, currently worth about US$103m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. An insider hasn't bought Elevance Health stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of Elevance Health. But note: Elevance Health may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store